GE HealthCare has unveiled a new radiation therapy (RT) computed tomography (CT) solution dubbed Revolution RT to boost imaging accuracy.
Revolution RT comes with several hardware and software solutions to streamline simulation workflow and provide more customised and seamless oncology care.
The Nasdaq-listed GE HealthCare has designed the Revolution RT with a wide-bore CT platform and radiation therapy simulation, diagnostic, and interventional features for accommodating more patients.
The radiation therapy has deep learning technology-powered precision radiotherapy simulation to enhance imaging accuracy, workflow, and efficiency.
The new Revolution RT solution is being launched at the 2024 European Society for Therapeutic Radiology and Oncology (ESTRO) Congress in Glasgow. Scotland.
In addition, the healthcare technology firm is introducing an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy (iRT) platform.
GE HealthCare will also unveil its newly acquired MIM Software portfolio.
The new iRT platform, originally launched at ESTRO 2023, interfaces with the Spectronic magnetic resonance imaging (MRI) Planner.
The solution has features like integrated workflow, multi-vendor interoperability, seamless data transfer and task automation, and a range of RT applications from both GE HealthCare and third parties.
Furthermore, the addition of MIM Software to GE HealthCare’s portfolio brings new imaging analytics and digital workflow tools. It boosts flexibility, automation, and efficiency for providers, the healthcare technology firm said.
Additionally, the acquisition strengthens GE HealthCare’s partnership with Elekta, a precise radiation therapy firm.
The MIM Software will be integrated with Elekta’s treatment planning software to deliver radiation therapy by enabling precision dose calculation.
GE HealthCare chief technology and science officer Taha Kass-Hout said: “Our showcase at ESTRO this year highlights innovations that will allow clinicians to view the patient’s anatomy with great accuracy, helping facilitate precise tumour targeting while aiming to protect nearby healthy tissue.
“By integrating these capabilities into our systems, we create a precise, more connected, and efficient care environment that accelerates the delivery of personalised care, with the goal of enabling better patient outcomes.
“This comprehensive approach empowers clinicians around the globe to tackle the most challenging disease states with precision and efficiency.”
